- Email: [email protected]
experimental treatment and carcinogenesis
HEPATOLOGYVol. 22, No. 4, Pt. 2, 1995
AASLD PROGRAM
Sunday #353
#354
#355
Follow-up of French patients with HCV-related cirrhosis: incidence of h e p a t o c e l l u l a r c a r c i n o m a and mortality. C Christidis, N Ganne-Carri~, C Chastang, D Pateron, JC Trinchet and M Beaugrand. Serv. d'Hepato-Gastro., Hop. Jean Verdier, Bondy and Dept. de Biostatistique, Hop. Saint-Louis, Paris, France.
HCV g e n o t y p e s and h e p a t o c e l l u l a r carcinoma. R Bottelli, E Silini, G Iamoni, F Gelosa, L Belli, A Bellobuono, L Mondazzi, C Zavaglia and G Id~o. Div. of Med. and Ctr. for Liver Diseases "Crepsi", Niguarda Hosp., Milan and Inst. of Pathol., Univ. of Pavia, Italy. G e n o t y p e s / a m o u n t o f HCV, b a c k g r o u n d l i v e r d i s e a s e and HCC recurrence. N Kato, S Shiina, M Imamura, F Kanai, T Okudaira, T Teratani, PY Zhang, H Yoshida, T Kawabe, S Ohta, Y Shiratori and M Omata. 2nd Dept. of Internal Med., Faculty of Med., Univ. of Tokyo, Japan.
Posters #360
D e v e l o p m e n t o f a n o v e l retroviral vector transferring a suicide gene driven b y a t e t r a c y c l i n e - r e s p o n s i v e expression system. J-J Hwang and WF Anderson. Norris Cancer Ctr., USC Sch. of Med., Los Angeles, CA.
#361
Mechanisms w h e r e b y a s y n t h e t i c phosphatidylcholine-specifie phospholipase D activator overcomes m u l t i d r u g r e s i s t a n c e in h u m a n h e p a t o c e l l u l a r c a r c i n o m a cells. L Marucci, L Varticovski and IM Arias. Physiol. Dept., Tufts Med. Sch., Boston, MA.
#362
A n t i b o d i e s to t u m o r n e c r o s i s f a c t o r - a inhibit cell r e p l i c a t i o n c a u s e d b y t h e p e r o x i s o m e p r o l i f e r a t o r WY-14,643. HK Bojes, DR Germolec, A Bruccoleri, R Schoonhoven, MI Luster and RG Thurman. Dept. of Pharmacol. and Curriculum in Toxicol., Dept. of Environ. Sci. & Engineering, Univ. of North Carolina, Chapel Hill and Immunol. and Neurobiol. Section, NIEHS, Research Triangle Park, NC.
#363
I n t e r f e r o n r e g u l a t o r y f a c t o r - 1 gene: e f f e c t o n h e p a t o m a cell g r o w t h in r e s p o n s e to i n t e r f e r o n . S Tada, H Saito, H Ebinuma and H Ishii. Dept. of Internal Med., Sch. of Med., Keio Univ., Tokyo, Japan.
#364
Inhibition o f cell g r o w t h o f h u m a n h e p a t o m a cell l i n e ( H e p G2) b y a f a r n e s y l t r a n s f e r a s e inhibitor: a selective suppression of Ras farnesylation. T Nagase, S Kawata, S Tamura, Y Matsuda, Y Inui, E Yamasaki, H Ishiguro, T Ito and Y Matsuzawa. 2nd Dept. of Internal Med., Osaka Univ. Med. Sch., Suita, Japan.
#365
Topoisomerase I inhibitors induce apoptosis in a human hepatocellular c a r c i n o m a cell l i n e b y a p r o t e a s e sensitive pathway. PN Adje~, SH Kaufmann and GJ Gores. Mayo Clinic, Rochester, MN.
#366
Inhibiting M o r r i s h e p a t o m a g r o w t h in r a t s b y b l o c k i n g l a t e c h o l e s t e r o l synthesis, G Xu, G Salen, M Lee, S Shefer, A Honda, T Chen and GS Tint. GI Lab, VA Med. Ctr., East Orange, NJ.
#367
Polypeptide growth factors participate in the process of malignant transformation of liver epithelial cells. P Steinberg, K Siegel, N Zhang, M Odenthal, R Becker, F Oesch, HP Dienes and P Schirmacher. Insts. of Toxicol. and Pathol., Univ. of Mainz, Germany.
LIVER CANCER: CLINICAL ~EXPERIMENTAL T R E A T M E N T A N D CARCINOGENESIS
#356
#357
#358
#359
P e r c u t a n e o u s i n t r a t u m o r a l injection o f Holmium-166 m i c r o a g g r e g a t e for the t r e a t m e n t o f small h e p a t o c e l l u l a r carcinoma. JT Lee, KH Han, JD Lee, HS Yoo, YM Moon and KB Park. Dept. of Radiol. and Internal Med., Yonsei Univ. and Korea Atomic Energy Research Inst., Seoul, Korea. P r o s p e c t i v e c o n t r o l l e d t r i a l of p e r c u t a n e o u s a c e t i c a c i d i n j e c t i o n f o r small h e p a t o c e l l u l a r carcinoma in c o m p a r i son with percutaneous ethanol injection. K Ohnishi, H Yoshioka, S Ito and K Fujiwara. 3rd Dept. of Med., Saitama Med. Sch., Iruma, Japan. T o l e r a n c e o f t h e h u m a n l i v e r to i n c r e a s i n g d o s e s o f intra-hepatic artery cisplatin for hepatocellular carcinoma. BI Carr. Pittsburgh Transplantation Inst., Univ. of Pittsburgh Sch. of Med., Pittsburgh, PA.
Effect o f a n t i a n d r o g e n t r e a t m e n t on h e p a t o c e l l u l a r carcinoma. B Matsuura, Y Taniguchi and M Onji. 3rd Dept. of Internal Med., Ehime Univ. Sch. of Med., Ehime, Japan.
49A
50A
AASLD PROGRAM
HEPATOLOGYOctober 1995
Sunday Posters #368
#369
#370
#371
#372
#373
R e g u l a t i o n o f Gia-protein e x p r e s s i o n in hepatocellular carcinoma p o s s i b l e r o l e in t u m o r growth. I McKillop, Y Wu, PA Cahill and JV Sitzmann. Johns Hopkins Med. Inst., Baltimore, MD.
LIVER TRANSPLANTATION: CLINICAL H
#374
Iron i n d u c e s b o t h D N A s y n t h e s i s and r e p a i r i n r a t h e p a t o c y t e stimulated by EGF/pyruvate. N Chenoufi, O Lor6al, B Dr6nou, S Cariou, N Hubert, P Leroyer, P Brissot and G Lescoat. INSERM U49, Unite de Recherches Hepatologiques, Lab. d'Hematol, et d'Immunol, and Clinique des Maladies du Foie, CHRU Pontchaillou, Rennes, France.
Liver t r a n s p l a n t a t i o n for small hepatocellular carcinoma in c i r r h o s i s : report o f t h e M i l a n p r o s p e c t i v e trial. V Mazzaferro, E Regalia, A Pulvirenti, S Andreola, D Baratti, R Doci, F Bozzetti and L Gennari. Liver Transplantation Unit, Inst. Nazionale Tumori, Milan, Italy.
#375
De novo malignancy following ortho-
How are capsule and septum formed during the growth of human hepatocellular carcinoma? K Ashida, H Nakatsukasa, T Higashi, N Hino, K Noso, Y Urabe, K Yoshida, N Kinugasa, S Uematsu and T Tsuji. 1st Dept. of Internal Med., Okayama Univ. Med. Sch., Okayama, Japan.
#376
In spite o f an i n c r e a s e d f r e q u e n c y o f p e r i o p e r a t i v e delirium, a l c o h o l i c patients h a v e favorable o u t c o m e s after liver transplantation. SS Johnson, DJ Plevak, EFM Wijdicks, JL Steers, SG Jowsey and RH Wiesner. Depts. ofAnesthesiol., Neurol., Surg., Psychiatry and Gastro., Mayo Clinic, Rochester, MN.
#377
R e c i d i v i s m f o l l o w i n g l i v e r transp l a n t a t i o n for a l c o h o l i c c i r r h o s i s . TC Gerhardt, RM Goldstein, DC Mulligan, MF Levy, BS Husberg, TA Gonwa and GB Klintmalm. Transplant Serv., Baylor Univ. Med. Ctr., Dallas, TX.
#378
Hepatic encephalopathy in patients s u b m i t t e d to liver t r a n s p l a n t a t i o n may b e p r e c i p i t a t e d b y b e n z o d i a z e pines present in transfused blood. ML Zeneroli, I Venturini, R Avallone, L Corsi, G Ardizzone, F Farina, A Nocera, M Centenaro and M Baraldi. Depts. of Internal Med. and Pharmaceutical Sciences, Modena Univ., Modena and Transplantation Unit and Immunol. Serv., S. Martino Hosp., Genoa, Italy.
#379
Effect of l i v e r t r a n s p l a n t a t i o n on hepatic encephalopathy and hyperi n t e n s e g l o b u s p a l l i d u s on Tl-weighted M R I in l i v e r failure: r e s u l t s o f a prospective study. S Herrmann, D Krieger, O Jansen, L Theilmann, M Geissler, W Stremmel and G Otto. Depts. of Gastro., Neurol., Neuroradiol., Psychiat. and Surg., Ruprecht-Karls Univ. of Heidelberg, Germany.
Role o f signal t r a n s d u c t i o n p a t h w a y s in hepatic transformation induced by o v e r e x p r e s s i o n o f t h e h u m a n insulin receptor substrate-1. T Ito, S Tanaka and JR Wands. Molecular Hepatol. Lab., MGH Cancer Ctr., Massachusetts Gen. Hosp. and Harvard Med. Sch., Charlestown, MA. Analysis o f g e n e and p r o t e i n e x p r e s s i o n o f HLA-class I m o l e c u l e s and the transporter associated with antigen p r o c e s s i n g in h e p a t o c e l l u l a r carcinoma. K Kurokohchi, M Carrington, D Mann, TB Simonis, SM Feinstone, T Akatsuka and JA Berzofsky. Metabolism Branch, NCI/NIH, Bethesda, Immunogenetics Section, NCI/ NIH, FrederickDiv. ofVirol., FDA and Dept. of Transfusion Med., NIH, Bethesda, MD. H e p a t i c m e t a s t a s i s o f h u m a n color e c t a l c a n c e r x e n o g r a f t s in SCID mice. HL Bumpers, TR Alosco, HQ Wang, NJ Petrelli, EL Hoover and RB Bankert. Dept. of Surg., Div. of Surg. Oncol., State Univ. of New York and Molecular Immunol., Roswell Park Cancer Inst., Buffalo, NY.
t o p i c l i v e r t r a n s p l a n t a t i o n for alcoholic cirrhosis. C Vanlemmens, S Bresson-Hadni, E Monnet, S Hrusovsky, MC Becker, A Minello, B Heyd, G Mantion, B Kantelip, P Hillon and JP Miguet. Unite de Transplantation Hepatique, CHU Jean Minjoz, Besancon, France.
AASLD PROGRAM
Sunday #353
#354
#355
Follow-up of French patients with HCV-related cirrhosis: incidence of h e p a t o c e l l u l a r c a r c i n o m a and mortality. C Christidis, N Ganne-Carri~, C Chastang, D Pateron, JC Trinchet and M Beaugrand. Serv. d'Hepato-Gastro., Hop. Jean Verdier, Bondy and Dept. de Biostatistique, Hop. Saint-Louis, Paris, France.
HCV g e n o t y p e s and h e p a t o c e l l u l a r carcinoma. R Bottelli, E Silini, G Iamoni, F Gelosa, L Belli, A Bellobuono, L Mondazzi, C Zavaglia and G Id~o. Div. of Med. and Ctr. for Liver Diseases "Crepsi", Niguarda Hosp., Milan and Inst. of Pathol., Univ. of Pavia, Italy. G e n o t y p e s / a m o u n t o f HCV, b a c k g r o u n d l i v e r d i s e a s e and HCC recurrence. N Kato, S Shiina, M Imamura, F Kanai, T Okudaira, T Teratani, PY Zhang, H Yoshida, T Kawabe, S Ohta, Y Shiratori and M Omata. 2nd Dept. of Internal Med., Faculty of Med., Univ. of Tokyo, Japan.
Posters #360
D e v e l o p m e n t o f a n o v e l retroviral vector transferring a suicide gene driven b y a t e t r a c y c l i n e - r e s p o n s i v e expression system. J-J Hwang and WF Anderson. Norris Cancer Ctr., USC Sch. of Med., Los Angeles, CA.
#361
Mechanisms w h e r e b y a s y n t h e t i c phosphatidylcholine-specifie phospholipase D activator overcomes m u l t i d r u g r e s i s t a n c e in h u m a n h e p a t o c e l l u l a r c a r c i n o m a cells. L Marucci, L Varticovski and IM Arias. Physiol. Dept., Tufts Med. Sch., Boston, MA.
#362
A n t i b o d i e s to t u m o r n e c r o s i s f a c t o r - a inhibit cell r e p l i c a t i o n c a u s e d b y t h e p e r o x i s o m e p r o l i f e r a t o r WY-14,643. HK Bojes, DR Germolec, A Bruccoleri, R Schoonhoven, MI Luster and RG Thurman. Dept. of Pharmacol. and Curriculum in Toxicol., Dept. of Environ. Sci. & Engineering, Univ. of North Carolina, Chapel Hill and Immunol. and Neurobiol. Section, NIEHS, Research Triangle Park, NC.
#363
I n t e r f e r o n r e g u l a t o r y f a c t o r - 1 gene: e f f e c t o n h e p a t o m a cell g r o w t h in r e s p o n s e to i n t e r f e r o n . S Tada, H Saito, H Ebinuma and H Ishii. Dept. of Internal Med., Sch. of Med., Keio Univ., Tokyo, Japan.
#364
Inhibition o f cell g r o w t h o f h u m a n h e p a t o m a cell l i n e ( H e p G2) b y a f a r n e s y l t r a n s f e r a s e inhibitor: a selective suppression of Ras farnesylation. T Nagase, S Kawata, S Tamura, Y Matsuda, Y Inui, E Yamasaki, H Ishiguro, T Ito and Y Matsuzawa. 2nd Dept. of Internal Med., Osaka Univ. Med. Sch., Suita, Japan.
#365
Topoisomerase I inhibitors induce apoptosis in a human hepatocellular c a r c i n o m a cell l i n e b y a p r o t e a s e sensitive pathway. PN Adje~, SH Kaufmann and GJ Gores. Mayo Clinic, Rochester, MN.
#366
Inhibiting M o r r i s h e p a t o m a g r o w t h in r a t s b y b l o c k i n g l a t e c h o l e s t e r o l synthesis, G Xu, G Salen, M Lee, S Shefer, A Honda, T Chen and GS Tint. GI Lab, VA Med. Ctr., East Orange, NJ.
#367
Polypeptide growth factors participate in the process of malignant transformation of liver epithelial cells. P Steinberg, K Siegel, N Zhang, M Odenthal, R Becker, F Oesch, HP Dienes and P Schirmacher. Insts. of Toxicol. and Pathol., Univ. of Mainz, Germany.
LIVER CANCER: CLINICAL ~EXPERIMENTAL T R E A T M E N T A N D CARCINOGENESIS
#356
#357
#358
#359
P e r c u t a n e o u s i n t r a t u m o r a l injection o f Holmium-166 m i c r o a g g r e g a t e for the t r e a t m e n t o f small h e p a t o c e l l u l a r carcinoma. JT Lee, KH Han, JD Lee, HS Yoo, YM Moon and KB Park. Dept. of Radiol. and Internal Med., Yonsei Univ. and Korea Atomic Energy Research Inst., Seoul, Korea. P r o s p e c t i v e c o n t r o l l e d t r i a l of p e r c u t a n e o u s a c e t i c a c i d i n j e c t i o n f o r small h e p a t o c e l l u l a r carcinoma in c o m p a r i son with percutaneous ethanol injection. K Ohnishi, H Yoshioka, S Ito and K Fujiwara. 3rd Dept. of Med., Saitama Med. Sch., Iruma, Japan. T o l e r a n c e o f t h e h u m a n l i v e r to i n c r e a s i n g d o s e s o f intra-hepatic artery cisplatin for hepatocellular carcinoma. BI Carr. Pittsburgh Transplantation Inst., Univ. of Pittsburgh Sch. of Med., Pittsburgh, PA.
Effect o f a n t i a n d r o g e n t r e a t m e n t on h e p a t o c e l l u l a r carcinoma. B Matsuura, Y Taniguchi and M Onji. 3rd Dept. of Internal Med., Ehime Univ. Sch. of Med., Ehime, Japan.
49A
50A
AASLD PROGRAM
HEPATOLOGYOctober 1995
Sunday Posters #368
#369
#370
#371
#372
#373
R e g u l a t i o n o f Gia-protein e x p r e s s i o n in hepatocellular carcinoma p o s s i b l e r o l e in t u m o r growth. I McKillop, Y Wu, PA Cahill and JV Sitzmann. Johns Hopkins Med. Inst., Baltimore, MD.
LIVER TRANSPLANTATION: CLINICAL H
#374
Iron i n d u c e s b o t h D N A s y n t h e s i s and r e p a i r i n r a t h e p a t o c y t e stimulated by EGF/pyruvate. N Chenoufi, O Lor6al, B Dr6nou, S Cariou, N Hubert, P Leroyer, P Brissot and G Lescoat. INSERM U49, Unite de Recherches Hepatologiques, Lab. d'Hematol, et d'Immunol, and Clinique des Maladies du Foie, CHRU Pontchaillou, Rennes, France.
Liver t r a n s p l a n t a t i o n for small hepatocellular carcinoma in c i r r h o s i s : report o f t h e M i l a n p r o s p e c t i v e trial. V Mazzaferro, E Regalia, A Pulvirenti, S Andreola, D Baratti, R Doci, F Bozzetti and L Gennari. Liver Transplantation Unit, Inst. Nazionale Tumori, Milan, Italy.
#375
De novo malignancy following ortho-
How are capsule and septum formed during the growth of human hepatocellular carcinoma? K Ashida, H Nakatsukasa, T Higashi, N Hino, K Noso, Y Urabe, K Yoshida, N Kinugasa, S Uematsu and T Tsuji. 1st Dept. of Internal Med., Okayama Univ. Med. Sch., Okayama, Japan.
#376
In spite o f an i n c r e a s e d f r e q u e n c y o f p e r i o p e r a t i v e delirium, a l c o h o l i c patients h a v e favorable o u t c o m e s after liver transplantation. SS Johnson, DJ Plevak, EFM Wijdicks, JL Steers, SG Jowsey and RH Wiesner. Depts. ofAnesthesiol., Neurol., Surg., Psychiatry and Gastro., Mayo Clinic, Rochester, MN.
#377
R e c i d i v i s m f o l l o w i n g l i v e r transp l a n t a t i o n for a l c o h o l i c c i r r h o s i s . TC Gerhardt, RM Goldstein, DC Mulligan, MF Levy, BS Husberg, TA Gonwa and GB Klintmalm. Transplant Serv., Baylor Univ. Med. Ctr., Dallas, TX.
#378
Hepatic encephalopathy in patients s u b m i t t e d to liver t r a n s p l a n t a t i o n may b e p r e c i p i t a t e d b y b e n z o d i a z e pines present in transfused blood. ML Zeneroli, I Venturini, R Avallone, L Corsi, G Ardizzone, F Farina, A Nocera, M Centenaro and M Baraldi. Depts. of Internal Med. and Pharmaceutical Sciences, Modena Univ., Modena and Transplantation Unit and Immunol. Serv., S. Martino Hosp., Genoa, Italy.
#379
Effect of l i v e r t r a n s p l a n t a t i o n on hepatic encephalopathy and hyperi n t e n s e g l o b u s p a l l i d u s on Tl-weighted M R I in l i v e r failure: r e s u l t s o f a prospective study. S Herrmann, D Krieger, O Jansen, L Theilmann, M Geissler, W Stremmel and G Otto. Depts. of Gastro., Neurol., Neuroradiol., Psychiat. and Surg., Ruprecht-Karls Univ. of Heidelberg, Germany.
Role o f signal t r a n s d u c t i o n p a t h w a y s in hepatic transformation induced by o v e r e x p r e s s i o n o f t h e h u m a n insulin receptor substrate-1. T Ito, S Tanaka and JR Wands. Molecular Hepatol. Lab., MGH Cancer Ctr., Massachusetts Gen. Hosp. and Harvard Med. Sch., Charlestown, MA. Analysis o f g e n e and p r o t e i n e x p r e s s i o n o f HLA-class I m o l e c u l e s and the transporter associated with antigen p r o c e s s i n g in h e p a t o c e l l u l a r carcinoma. K Kurokohchi, M Carrington, D Mann, TB Simonis, SM Feinstone, T Akatsuka and JA Berzofsky. Metabolism Branch, NCI/NIH, Bethesda, Immunogenetics Section, NCI/ NIH, FrederickDiv. ofVirol., FDA and Dept. of Transfusion Med., NIH, Bethesda, MD. H e p a t i c m e t a s t a s i s o f h u m a n color e c t a l c a n c e r x e n o g r a f t s in SCID mice. HL Bumpers, TR Alosco, HQ Wang, NJ Petrelli, EL Hoover and RB Bankert. Dept. of Surg., Div. of Surg. Oncol., State Univ. of New York and Molecular Immunol., Roswell Park Cancer Inst., Buffalo, NY.
t o p i c l i v e r t r a n s p l a n t a t i o n for alcoholic cirrhosis. C Vanlemmens, S Bresson-Hadni, E Monnet, S Hrusovsky, MC Becker, A Minello, B Heyd, G Mantion, B Kantelip, P Hillon and JP Miguet. Unite de Transplantation Hepatique, CHU Jean Minjoz, Besancon, France.